Table 6.
Diagnostic value of miRNAs in psoriasis patients.
| miRNA | Numbers of clinical samples | Distinguish between | Area under curve (AUC) | Sensitivity | Specificity | Reference |
|---|---|---|---|---|---|---|
| miR-126 | 147 psoriasis patients and 120 healthy volunteers were enrolled in this clinical study. | Distinguishes psoriasis patients from normal subjects. | 0.771 | 57.1% | 87.5% | [35] |
| miR-143 | In total, 194 psoriasis patients and 175 healthy controls were recruited. | Distinguishes psoriasis patients from normal subjects. | 0.886 | 78.5% | 97.1% | [36] |
| Distinguishes progressive stage | 0.884 | 75.5% | 90.3% | |||
| Distinguishes stable stage | 0.833 | 60.9% | 97.1% | |||
| miR-19a | 18 patients with psoriasis and 22 healthy controls were recruited. | Distinguishes psoriasis patients from normal subjects. | 0.87 | [56] | ||
| miR-155 | 11 patients with psoriasis and 11 healthy age- and gender-matched volunteers participated in this study. | Distinguishes psoriasis patients from normal subjects. | 0.955 | 0.91 | 0.9 | [46] |